Loratadine ODT

Manufacturer
Chain Drug Consortium, LLC | Ranbaxy Pharmaceuticals Inc. | Ohm Laboratories Inc.
Effective date
2015-10-08
Label type
HUMAN OTC DRUG LABEL
Version
3
Source
full-release
Hydrated at
2026-05-31 22:43:50

Label at a glance#

ProductLoratadine ODT
Active ingredientLORATADINE
Label structure9 sections

Indications and uses

temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: • runny nose • itchy, watery eyes • sneezing • itching of the nose or throat

Dosage and administration

• place 1 tablet on tongue; tablet disintegrates, with or without water adults and children 6 years and over 1 tablet daily; not more than 1 tablet in 24 hours children under 6 years of age ask a doctor consumers with liver or kidney disease ask a doctor

Label contents#

Full prescribing information#

ACTIVE INGREDIENT (IN EACH TABLET)

OTC - ACTIVE INGREDIENT SECTION

Loratadine, USP 10 mg

PURPOSE

OTC - PURPOSE SECTION

Antihistamine

USES

INDICATIONS & USAGE SECTION

temporarily relieves these symptoms due to hay fever or other upper respiratory allergies:

  • runny nose
  • itchy, watery eyes
  • sneezing
  • itching of the nose or throat

WARNINGS

WARNINGS SECTION

Do not use

OTC - DO NOT USE SECTION

if you have ever had an allergic reaction to this product or any of its ingredients.

Ask a doctor before use if you have

OTC - ASK DOCTOR SECTION

liver or kidney disease. Your doctor should determine if you need a different dose.

When using this product

OTC - WHEN USING SECTION

do not take more than directed. Taking more than directed may cause drowsiness.

Stop use and ask a doctor if

OTC - STOP USE SECTION

an allergic reaction to this product occurs. Seek medical help right away.

If pregnant or breast-feeding,

OTC - PREGNANCY OR BREAST FEEDING SECTION

ask a health professional before use.

Keep out of reach of children.

OTC - KEEP OUT OF REACH OF CHILDREN SECTION

In case of overdose, get medical help or contact a Poison Control Center right away (1-800-222-1222).

DIRECTIONS

DOSAGE & ADMINISTRATION SECTION

  • place 1 tablet on tongue; tablet disintegrates, with or without water

adults and children 6 years and over

1 tablet daily; not more than 1 tablet in 24 hours

children under 6 years of age

ask a doctor

consumers with liver or kidney disease

ask a doctor

OTHER INFORMATION

SPL UNCLASSIFIED SECTION

  • Phenylketonurics: Contains Phenylalanine 0.6 mg Per Tablet.
  • TAMPER EVIDENT: DO NOT USE IF BLISTER UNITS ARE TORN, BROKEN OR SHOW ANY SIGNS OF TAMPERING.
  • store between 20° to 25° C (68° to 77° F). Protect from excessive moisture.
  • keep in a dry place.
  • use tablet immediately after opening individual blister.

INACTIVE INGREDIENTS

INACTIVE INGREDIENT SECTION

aspartame, croscarmellose sodium, fruit flavors, magnesium stearate, mannitol, sodium stearyl fumarate

QUESTIONS?

OTC - QUESTIONS SECTION

call 1-800-406-7984

Keep the carton. It contains important information.

See end panel for expiration date.

DISTRIBUTED BY

CHAIN DRUG CONSORTIUM

3301 NW BOCA RATON BLVD

SUITE 101, BOCA RATON, FL 33431

PRINCIPAL DISPLAY PANEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Premier Value®

NDC 68016-527-31

Original Prescription Strength

NON-DROWSY*

24 Hour Allergy Relief

Loratadine Orally Disintegrating Tablets, 10 mg

Allergy Relief

Antihistamine

Indoor & Outdoor Allergies

No water needed. Melts in your mouth.

Relief of:

  • Sneezing
  • Itchy, Watery Eyes
  • Runny Nose
  • Itchy Throat or Nose

For Adults and Children six years and older!

30 ORALLY DISINTEGRATING TABLETS

COMPARE TO THE ACTIVE INGREDIENT OF CLARITIN®REDITABS®†

*When taken as directed. See Drug Facts Panel.

†This product is not manufactured or distributed by Schering-Plough HealthCare Products, Inc. CLARITIN® and REDITABS® are registered trademarks of Schering Corporation.

This is the 30 count blister carton label for Premier Value Loratadine ODT, USP 10 mg.
This is the 30 count blister carton label for Premier Value Loratadine ODT, USP 10 mg.

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
311373loratadine 10 MG 24HR Disintegrating Oral TabletPSN3
311373loratadine 10 MG Disintegrating Oral TabletSCD3

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
a62a50ac-1535-4461-9768-8ae703e2e9fbProduct name120210525
9514609b-a2a9-f8ec-6ba6-3f8e5ee89877Product name120140508
bc07ef78-e82d-0c19-31f4-31f263780582Product name120140508

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
68016-527-312020-01-31C16284748780-19d75b9d0-4e7f-f424-e053-dadaa90a57ceDrug Facts

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
68016-527-31Loratadine ODT30 in 1 BLISTER PACKTABLET, ORALLY DISINTEGRATING303

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
68016-527LORATADINE ODT (LORATADINE) TABLET, ORALLY DISINTEGRATING [CHAIN DRUG CONSORTIUM, LLC]3Legacy NDC, 1 package rows20151014_26a7a473-3b88-4aa6-be56-da315e7556b6.zip

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
LORATADINEACTIVE INGREDIENT7AJO3BO7QN3
LORATADINEACTIVE MOIETY7AJO3BO7QN3
ASPARTAMEINACTIVE INGREDIENTZ0H242BBR13
CROSCARMELLOSE SODIUMINACTIVE INGREDIENTM28OL1HH483
MAGNESIUM STEARATEINACTIVE INGREDIENT70097M6I303
MANNITOLINACTIVE INGREDIENT3OWL53L36A3
SODIUM STEARYL FUMARATEINACTIVE INGREDIENT7CV7WJK4UI3

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 7 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
68016-52768016-527-31

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 6 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 3 · 162 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
MANNITOLMANNITOL3OWL53L36APOWDER / ORAL4352 mgExact identifier — unii candidate
65 equally ranked IID candidates
MANNITOLMANNITOL3OWL53L36ATABLET, CHEWABLE, EXTENDED RELEASE / ORAL616 mgExact identifier — unii candidate
65 equally ranked IID candidates
SODIUM STEARYL FUMARATESODIUM STEARYL FUMARATE7CV7WJK4UILOZENGE / ORAL125 mgExact identifier — unii candidate
17 equally ranked IID candidates
CROSCARMELLOSE SODIUMCROSCARMELLOSE SODIUMM28OL1HH48TABLET, DELAYED RELEASE PARTICLES / ORAL64 mgExact identifier — unii candidate
22 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30PELLET / ORAL24 mgExact identifier — unii candidate
39 equally ranked IID candidates
MANNITOLMANNITOL3OWL53L36AINJECTION, SUSPENSION / INTRAVENOUS2.5 %w/vExact identifier — unii candidate
65 equally ranked IID candidates
SODIUM STEARYL FUMARATESODIUM STEARYL FUMARATE7CV7WJK4UITABLET / SUBLINGUAL29 mgExact identifier — unii candidate
17 equally ranked IID candidates
ASPARTAMEASPARTAMEZ0H242BBR1TABLET, CHEWABLE, EXTENDED RELEASE / ORAL18 mgExact identifier — unii candidate
19 equally ranked IID candidates
ASPARTAMEASPARTAMEZ0H242BBR1TABLET, FOR SUSPENSION / ORAL15 mgExact identifier — unii candidate
19 equally ranked IID candidates
SODIUM STEARYL FUMARATESODIUM STEARYL FUMARATE7CV7WJK4UIGRANULE, FOR SOLUTION / ORAL18.2 mg/120mlExact identifier — unii candidate
17 equally ranked IID candidates
MANNITOLMANNITOL3OWL53L36AGRANULE, FOR SUSPENSION / ORAL6000 mgExact identifier — unii candidate
65 equally ranked IID candidates
MANNITOLMANNITOL3OWL53L36AINJECTION, SUSPENSION / INTRAMUSCULAR71 mgExact identifier — unii candidate
65 equally ranked IID candidates
CROSCARMELLOSE SODIUMCROSCARMELLOSE SODIUMM28OL1HH48TABLET, COATED / ORAL224 mgExact identifier — unii candidate
22 equally ranked IID candidates
ASPARTAMEASPARTAMEZ0H242BBR1FILM, EXTENDED RELEASE / BUCCAL1 mgExact identifier — unii candidate
19 equally ranked IID candidates
ASPARTAMEASPARTAMEZ0H242BBR1POWDER, FOR SUSPENSION / ORAL420 mgExact identifier — unii candidate
19 equally ranked IID candidates
ASPARTAMEASPARTAMEZ0H242BBR1CAPSULE, EXTENDED RELEASE / ORAL3 mgExact identifier — unii candidate
19 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30TABLET, FOR SUSPENSION / ORAL131 mgExact identifier — unii candidate
39 equally ranked IID candidates
MANNITOLMANNITOL3OWL53L36AINJECTION, SOLUTION / INTRAVENOUS15400 mgExact identifier — unii candidate
65 equally ranked IID candidates
ASPARTAMEASPARTAMEZ0H242BBR1GRANULE, FOR SUSPENSION / ORAL420 mgExact identifier — unii candidate
19 equally ranked IID candidates
CROSCARMELLOSE SODIUMCROSCARMELLOSE SODIUMM28OL1HH48TROCHE / ORAL50 mgExact identifier — unii candidate
22 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30GRANULE / ORAL629 mgExact identifier — unii candidate
39 equally ranked IID candidates
MANNITOLMANNITOL3OWL53L36ATABLET, EXTENDED RELEASE / ORAL1086 mgExact identifier — unii candidate
65 equally ranked IID candidates
CROSCARMELLOSE SODIUMCROSCARMELLOSE SODIUMM28OL1HH48CAPSULE, COATED PELLETS / ORAL198 mgExact identifier — unii candidate
22 equally ranked IID candidates
MANNITOLMANNITOL3OWL53L36AINJECTION, POWDER, FOR SUSPENSION / INTRAVENOUS181 mgExact identifier — unii candidate
65 equally ranked IID candidates
MANNITOLMANNITOL3OWL53L36ATABLET / SUBLINGUAL495 mgExact identifier — unii candidate
65 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30GRANULE, FOR SUSPENSION / ORAL14 mgExact identifier — unii candidate
39 equally ranked IID candidates
SODIUM STEARYL FUMARATESODIUM STEARYL FUMARATE7CV7WJK4UITABLET, DELAYED RELEASE / ORAL216 mgExact identifier — unii candidate
17 equally ranked IID candidates
ASPARTAMEASPARTAMEZ0H242BBR1TABLET, CHEWABLE / ORAL195 mgExact identifier — unii candidate
19 equally ranked IID candidates
MANNITOLMANNITOL3OWL53L36ATABLET, ORALLY DISINTEGRATING / ORAL4364 mgExact identifier — unii candidate
65 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30TABLET / BUCCAL17.5 mgExact identifier — unii candidate
39 equally ranked IID candidates
MANNITOLMANNITOL3OWL53L36AINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAMUSCULAR113 mgExact identifier — unii candidate
65 equally ranked IID candidates
CROSCARMELLOSE SODIUMCROSCARMELLOSE SODIUMM28OL1HH48CAPSULE, DELAYED RELEASE / ORAL72 mgExact identifier — unii candidate
22 equally ranked IID candidates
MANNITOLMANNITOL3OWL53L36ACAPSULE, DELAYED RELEASE / ORAL2043 mgExact identifier — unii candidate
65 equally ranked IID candidates
MANNITOLMANNITOL3OWL53L36ACAPSULE, EXTENDED RELEASE / ORAL160 mgExact identifier — unii candidate
65 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30POWDER / RESPIRATORY (INHALATION)0.13 mgExact identifier — unii candidate
39 equally ranked IID candidates
MANNITOLMANNITOL3OWL53L36AINJECTION / INTRAVENOUS15200 mgExact identifier — unii candidate
65 equally ranked IID candidates
CROSCARMELLOSE SODIUMCROSCARMELLOSE SODIUMM28OL1HH48TABLET, DELAYED RELEASE / ORAL280 mgExact identifier — unii candidate
22 equally ranked IID candidates
CROSCARMELLOSE SODIUMCROSCARMELLOSE SODIUMM28OL1HH48GRANULE / ORAL150 mgExact identifier — unii candidate
22 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30TABLET, EXTENDED RELEASE / ORAL173 mgExact identifier — unii candidate
39 equally ranked IID candidates
CROSCARMELLOSE SODIUMCROSCARMELLOSE SODIUMM28OL1HH48GRANULE, FOR SUSPENSION / ORAL282 mgExact identifier — unii candidate
22 equally ranked IID candidates
ASPARTAMEASPARTAMEZ0H242BBR1SUSPENSION / ORAL23 mgExact identifier — unii candidate
19 equally ranked IID candidates
MANNITOLMANNITOL3OWL53L36AINJECTION, SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR105 mgExact identifier — unii candidate
65 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30DROPS / ORALNAExact identifier — unii candidate
39 equally ranked IID candidates
CROSCARMELLOSE SODIUMCROSCARMELLOSE SODIUMM28OL1HH48PELLET / ORAL162 mgExact identifier — unii candidate
22 equally ranked IID candidates
MANNITOLMANNITOL3OWL53L36AINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS15400 mgExact identifier — unii candidate
65 equally ranked IID candidates
MANNITOLMANNITOL3OWL53L36ASUSPENSION/ DROPS / TOPICAL0.3 %w/vExact identifier — unii candidate
65 equally ranked IID candidates
SODIUM STEARYL FUMARATESODIUM STEARYL FUMARATE7CV7WJK4UITABLET, FOR SUSPENSION / ORAL435 mgExact identifier — unii candidate
17 equally ranked IID candidates
MANNITOLMANNITOL3OWL53L36ASOLUTION, CONCENTRATE / INTRAVENOUS220 mgExact identifier — unii candidate
65 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30TABLET, DELAYED RELEASE / ORAL144 mgExact identifier — unii candidate
39 equally ranked IID candidates
MANNITOLMANNITOL3OWL53L36ASOLUTION / SUBCUTANEOUS4.54 %w/vExact identifier — unii candidate
65 equally ranked IID candidates
MANNITOLMANNITOL3OWL53L36ALOZENGE / ORAL20546 mgExact identifier — unii candidate
65 equally ranked IID candidates
CROSCARMELLOSE SODIUMCROSCARMELLOSE SODIUMM28OL1HH48INJECTION / INTRAMUSCULAR1 %w/vExact identifier — unii candidate
22 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30TABLET / ORAL980 mgExact identifier — unii candidate
39 equally ranked IID candidates
MANNITOLMANNITOL3OWL53L36APOWDER / RESPIRATORY (INHALATION)6 mgExact identifier — unii candidate
65 equally ranked IID candidates
SODIUM STEARYL FUMARATESODIUM STEARYL FUMARATE7CV7WJK4UIPELLET / ORAL43 mgExact identifier — unii candidate
17 equally ranked IID candidates
MANNITOLMANNITOL3OWL53L36ASUSPENSION/ DROPS / OPHTHALMIC3.3 %w/vExact identifier — unii candidate
65 equally ranked IID candidates
MANNITOLMANNITOL3OWL53L36ATABLET, FILM COATED / ORAL2309 mgExact identifier — unii candidate
65 equally ranked IID candidates
ASPARTAMEASPARTAMEZ0H242BBR1POWDER / ORAL63 mgExact identifier — unii candidate
19 equally ranked IID candidates
ASPARTAMEASPARTAMEZ0H242BBR1SYRUP / ORAL0.63 mg/5mlExact identifier — unii candidate
19 equally ranked IID candidates
MANNITOLMANNITOL3OWL53L36AINJECTION, POWDER, FOR SOLUTION / PARENTERAL200 mgExact identifier — unii candidate
65 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A077153-001LORATADINE REDIDOSELORATADINE10MGTABLET, ORALLY DISINTEGRATING / ORAL2007-04-11

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A077153-001LORATADINE REDIDOSE10MGTABLET, ORALLY DISINTEGRATING / ORAL2007-04-1184e616aacf4f…
2026-08-18 06:07:402026-07A077153-001LORATADINE REDIDOSE10MGTABLET, ORALLY DISINTEGRATING / ORAL2007-04-11caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A077153-001LORATADINE REDIDOSE10MGTABLET, ORALLY DISINTEGRATING / ORAL2007-04-11011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A077153-001LORATADINE REDIDOSE10MGTABLET, ORALLY DISINTEGRATING / ORAL2007-04-1131067a03dcf5…
2025-08-23 18:47 UTC2025-08A077153-001LORATADINE REDIDOSE10MGTABLET, ORALLY DISINTEGRATING / ORAL2007-04-116a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A077153-001LORATADINE REDIDOSE10MGTABLET, ORALLY DISINTEGRATING / ORAL2007-04-11fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A077153-001LORATADINE REDIDOSE10MGTABLET, ORALLY DISINTEGRATING / ORAL2007-04-11b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A077153-001LORATADINE REDIDOSE10MGTABLET, ORALLY DISINTEGRATING / ORAL2007-04-1103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A077153-001LORATADINE REDIDOSE10MGTABLET, ORALLY DISINTEGRATING / ORAL2007-04-112680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A077153-001LORATADINE REDIDOSE10MGTABLET, ORALLY DISINTEGRATING / ORAL2007-04-115bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A077153-001LORATADINE REDIDOSE10MGTABLET, ORALLY DISINTEGRATING / ORAL2007-04-11d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A077153-001LORATADINE REDIDOSE10MGTABLET, ORALLY DISINTEGRATING / ORAL2007-04-11d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A077153-001LORATADINE REDIDOSE10MGTABLET, ORALLY DISINTEGRATING / ORAL2007-04-1179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A077153-001LORATADINE REDIDOSE10MGTABLET, ORALLY DISINTEGRATING / ORAL2007-04-11301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A077153-001LORATADINE REDIDOSE10MGTABLET, ORALLY DISINTEGRATING / ORAL2007-04-111e350fbaab3a…
2024-05-31 18:47 UTC2024-05A077153-001LORATADINE REDIDOSE10MGTABLET, ORALLY DISINTEGRATING / ORAL2007-04-118072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A077153-001LORATADINE REDIDOSE10MGTABLET, ORALLY DISINTEGRATING / ORAL2007-04-115c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A077153-001LORATADINE REDIDOSE10MGTABLET, ORALLY DISINTEGRATING / ORAL2007-04-115d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A077153-001LORATADINE REDIDOSE10MGTABLET, ORALLY DISINTEGRATING / ORAL2007-04-114b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A077153-001LORATADINE REDIDOSE10MGTABLET, ORALLY DISINTEGRATING / ORAL2007-04-1174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A077153-001LORATADINE REDIDOSE10MGTABLET, ORALLY DISINTEGRATING / ORAL2007-04-11bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A077153-001LORATADINE REDIDOSE10MGTABLET, ORALLY DISINTEGRATING / ORAL2007-04-11782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A077153-001LORATADINE REDIDOSE10MGTABLET, ORALLY DISINTEGRATING / ORAL2007-04-1187673890dc5c…
2021-03-12 10:30 UTC2021-03A077153-001LORATADINE REDIDOSE10MGTABLET, ORALLY DISINTEGRATING / ORAL2007-04-115aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A077153-001LORATADINE REDIDOSE10MGTABLET, ORALLY DISINTEGRATING / ORAL2007-04-118869cabd3fbd…
2020-11-12 02:37 UTC2020-11A077153-001LORATADINE REDIDOSE10MGTABLET, ORALLY DISINTEGRATING / ORAL2007-04-11c0c555d07b60…
2019-12-14 00:12 UTC2019-12A077153-001LORATADINE REDIDOSE10MGTABLET, ORALLY DISINTEGRATING / ORAL2007-04-113f01610625f2…
2019-09-15 20:21 UTC2019-09A077153-001LORATADINE REDIDOSE10MGTABLET, ORALLY DISINTEGRATING / ORAL2007-04-11b00525d2431f…
2019-07-19 19:46 UTC2019-07A077153-001LORATADINE REDIDOSE10MGTABLET, ORALLY DISINTEGRATING / ORAL2007-04-11ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A077153-001LORATADINE REDIDOSE10MGTABLET, ORALLY DISINTEGRATING / ORAL2007-04-116a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A077153-001LORATADINE REDIDOSE10MGTABLET, ORALLY DISINTEGRATING / ORAL2007-04-111c564ffb4f44…
2023-12-20 04:57 UTC2023-12A077153-001LORATADINE REDIDOSE10MGTABLET, ORALLY DISINTEGRATING / ORAL2007-04-11ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A077153-001LORATADINE REDIDOSE10MGTABLET, ORALLY DISINTEGRATING / ORAL2007-04-11a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A077153-001LORATADINE REDIDOSE10MGTABLET, ORALLY DISINTEGRATING / ORAL2007-04-119b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A077153-001LORATADINE REDIDOSE10MGTABLET, ORALLY DISINTEGRATING / ORAL2007-04-11a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A077153-001LORATADINE REDIDOSE10MGTABLET, ORALLY DISINTEGRATING / ORAL2007-04-113f0d92c62455…
2023-05-13 08:27 UTC2023-05A077153-001LORATADINE REDIDOSE10MGTABLET, ORALLY DISINTEGRATING / ORAL2007-04-11053a50430f4f…
2023-01-26 05:58 UTC2023-01A077153-001LORATADINE REDIDOSE10MGTABLET, ORALLY DISINTEGRATING / ORAL2007-04-113bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A077153-001LORATADINE REDIDOSE10MGTABLET, ORALLY DISINTEGRATING / ORAL2007-04-113a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A077153-001LORATADINE REDIDOSE10MGTABLET, ORALLY DISINTEGRATING / ORAL2007-04-11f41ea6bd6efb…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
ffe62d63-befe-4308-a676-12b3e179a32b26a7a473-3b88-4aa6-be56-da315e7556b62015-10-08WarningsExact identifier
spl id: ffe62d63-befe-4308-a676-12b3e179a32b
spl set id: 26a7a473-3b88-4aa6-be56-da315e7556b6

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.